GlaxoSmithKline Market Cap 2006-2019 | GSK

GlaxoSmithKline market cap history and chart from 2006 to 2019. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. GlaxoSmithKline market cap as of March 27, 2020 is $92.95B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.949B $43.102B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $333.683B 14.58
Roche Holding AG (RHHBY) Switzerland $265.584B 0.00
Merck (MRK) United States $186.492B 14.17
Novartis AG (NVS) Switzerland $182.748B 15.22
Pfizer (PFE) United States $176.138B 10.76
Novo Nordisk (NVO) Denmark $134.408B 23.07
Eli Lilly (LLY) United States $128.578B 22.24
Bristol-Myers Squibb (BMY) United States $117.955B 11.19
AstraZeneca (AZN) United Kingdom $111.168B 23.93
AbbVie (ABBV) United States $109.023B 8.26
Sanofi (SNY) France $107.553B 12.78
Bayer (BAYRY) Germany $53.155B 7.66
H Lundbeck (HLUYY) Denmark $5.819B 10.11